Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk

Varun Ashok, Chiranjeev Dash, Thomas E. Rohan, J. Michael Sprafka, Paul Terry

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: Recent epidemiologic and laboratory studies have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of cyclooxygenase-2 (COX-2). Methods: We conducted a case-control study to measure the association between selective cox-2 inhibitors, particularly celecoxib, rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk. Between 2003 and 2006, a total of 18,368 incident breast cancer cases were identified in the Ingenix/Lab Rx insurance database, which contains clinical encounter and drug prescription data. Four controls per case were randomly selected, matched on age and time in database. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using conditional logistic regression. Results: Breast cancer risk was inversely associated with both non-specific NSAID and selective COX-2 inhibitor use. Greater than 12 months' duration of use of Celecoxib at a standard dose (200. mg/day) was associated with a 16% decrease in breast cancer risk (OR = 0.84, 95% CI = 0.73, 0.97). We observed the greatest risk reduction in association with >2 years of rofecoxib exposure (OR = 0.54, 95% CI = 0.37, 0.80). Acetaminophen, a compound with less biological plausibility for chemoprevention, showed no significant association with the risk of developing breast cancer. Conclusion: Consistent with animal models and laboratory investigations, higher doses of selective COX-2 inhibitors were more protective against breast cancer than non-specific NSAIDs. With exposure to rofecoxib, a selective COX-2 inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective COX-2 inhibitors in breast cancer prophylaxis.

Original languageEnglish (US)
Pages (from-to)66-70
Number of pages5
JournalBreast
Volume20
Issue number1
DOIs
StatePublished - Feb 1 2011
Externally publishedYes

Fingerprint

Cyclooxygenase 2 Inhibitors
Breast Neoplasms
Celecoxib
Anti-Inflammatory Agents
Odds Ratio
Confidence Intervals
Risk Reduction Behavior
Pharmaceutical Preparations
Databases
Drug Prescriptions
Chemoprevention
Cyclooxygenase 2
Acetaminophen
Insurance
Case-Control Studies
Epidemiologic Studies
Animal Models
Logistic Models

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. / Ashok, Varun; Dash, Chiranjeev; Rohan, Thomas E.; Sprafka, J. Michael; Terry, Paul.

In: Breast, Vol. 20, No. 1, 01.02.2011, p. 66-70.

Research output: Contribution to journalArticle

Ashok, Varun ; Dash, Chiranjeev ; Rohan, Thomas E. ; Sprafka, J. Michael ; Terry, Paul. / Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. In: Breast. 2011 ; Vol. 20, No. 1. pp. 66-70.
@article{9b8bcae9125e41269f5d50fbdff9553a,
title = "Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk",
abstract = "Background: Recent epidemiologic and laboratory studies have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of cyclooxygenase-2 (COX-2). Methods: We conducted a case-control study to measure the association between selective cox-2 inhibitors, particularly celecoxib, rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk. Between 2003 and 2006, a total of 18,368 incident breast cancer cases were identified in the Ingenix/Lab Rx insurance database, which contains clinical encounter and drug prescription data. Four controls per case were randomly selected, matched on age and time in database. Odds ratios (OR) and 95{\%} confidence intervals (CI) were estimated using conditional logistic regression. Results: Breast cancer risk was inversely associated with both non-specific NSAID and selective COX-2 inhibitor use. Greater than 12 months' duration of use of Celecoxib at a standard dose (200. mg/day) was associated with a 16{\%} decrease in breast cancer risk (OR = 0.84, 95{\%} CI = 0.73, 0.97). We observed the greatest risk reduction in association with >2 years of rofecoxib exposure (OR = 0.54, 95{\%} CI = 0.37, 0.80). Acetaminophen, a compound with less biological plausibility for chemoprevention, showed no significant association with the risk of developing breast cancer. Conclusion: Consistent with animal models and laboratory investigations, higher doses of selective COX-2 inhibitors were more protective against breast cancer than non-specific NSAIDs. With exposure to rofecoxib, a selective COX-2 inhibitor, breast cancer risk reduction was appreciable (46{\%}), suggesting a possible role for selective COX-2 inhibitors in breast cancer prophylaxis.",
author = "Varun Ashok and Chiranjeev Dash and Rohan, {Thomas E.} and Sprafka, {J. Michael} and Paul Terry",
year = "2011",
month = "2",
day = "1",
doi = "10.1016/j.breast.2010.07.004",
language = "English (US)",
volume = "20",
pages = "66--70",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk

AU - Ashok, Varun

AU - Dash, Chiranjeev

AU - Rohan, Thomas E.

AU - Sprafka, J. Michael

AU - Terry, Paul

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Background: Recent epidemiologic and laboratory studies have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of cyclooxygenase-2 (COX-2). Methods: We conducted a case-control study to measure the association between selective cox-2 inhibitors, particularly celecoxib, rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk. Between 2003 and 2006, a total of 18,368 incident breast cancer cases were identified in the Ingenix/Lab Rx insurance database, which contains clinical encounter and drug prescription data. Four controls per case were randomly selected, matched on age and time in database. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using conditional logistic regression. Results: Breast cancer risk was inversely associated with both non-specific NSAID and selective COX-2 inhibitor use. Greater than 12 months' duration of use of Celecoxib at a standard dose (200. mg/day) was associated with a 16% decrease in breast cancer risk (OR = 0.84, 95% CI = 0.73, 0.97). We observed the greatest risk reduction in association with >2 years of rofecoxib exposure (OR = 0.54, 95% CI = 0.37, 0.80). Acetaminophen, a compound with less biological plausibility for chemoprevention, showed no significant association with the risk of developing breast cancer. Conclusion: Consistent with animal models and laboratory investigations, higher doses of selective COX-2 inhibitors were more protective against breast cancer than non-specific NSAIDs. With exposure to rofecoxib, a selective COX-2 inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective COX-2 inhibitors in breast cancer prophylaxis.

AB - Background: Recent epidemiologic and laboratory studies have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of cyclooxygenase-2 (COX-2). Methods: We conducted a case-control study to measure the association between selective cox-2 inhibitors, particularly celecoxib, rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk. Between 2003 and 2006, a total of 18,368 incident breast cancer cases were identified in the Ingenix/Lab Rx insurance database, which contains clinical encounter and drug prescription data. Four controls per case were randomly selected, matched on age and time in database. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using conditional logistic regression. Results: Breast cancer risk was inversely associated with both non-specific NSAID and selective COX-2 inhibitor use. Greater than 12 months' duration of use of Celecoxib at a standard dose (200. mg/day) was associated with a 16% decrease in breast cancer risk (OR = 0.84, 95% CI = 0.73, 0.97). We observed the greatest risk reduction in association with >2 years of rofecoxib exposure (OR = 0.54, 95% CI = 0.37, 0.80). Acetaminophen, a compound with less biological plausibility for chemoprevention, showed no significant association with the risk of developing breast cancer. Conclusion: Consistent with animal models and laboratory investigations, higher doses of selective COX-2 inhibitors were more protective against breast cancer than non-specific NSAIDs. With exposure to rofecoxib, a selective COX-2 inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective COX-2 inhibitors in breast cancer prophylaxis.

UR - http://www.scopus.com/inward/record.url?scp=79451475199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79451475199&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2010.07.004

DO - 10.1016/j.breast.2010.07.004

M3 - Article

VL - 20

SP - 66

EP - 70

JO - Breast

JF - Breast

SN - 0960-9776

IS - 1

ER -